Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wild-type disease

Journal of Clinical Oncology

Volumn 30, Issue 12, 2012, Pages 1255-1257

  Faris, Jason E ^a   Ryan, David P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

CANCER PROGNOSIS; CANCER STAGING; COLON CANCER; COLORECTAL CANCER; CPG ISLAND; EDITORIAL; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MICROARRAY ANALYSIS; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; COLON TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; MORTALITY; MUTATION; NOTE;

COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84862252529     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.1512     Document Type: Editorial

References (29)

1. Tejpar S, Bertagnolli M, Bosman F, et al: Prognostic and predictive biomarkers in resected colon cancer: Current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15:390-404, 2010
2. De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 11:753-762, 2010
3. Laurent-Puig P, Cayre A, Manceau G, et al: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924-5930, 2009
4. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
5. Tol J, Nagtegaal ID, Punt CJ: BRAF mutation in metastatic colorectal cancer. N Engl J Med 361:98-99, 2009
6. Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466-474, 2010
7. Ogino S, Shima K, Meyerhardt J, et al: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from Intergroup trial CALGB 89803. Clin Cancer Res 18:890-900, 2012
8. Yokota T, Ura T, Shibata N, et al: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104:856-862, 2011
9. Ogino S, Nosho K, Kirkner GJ, et al: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58:90-96, 2009
10. French AJ, Sargent DJ, Burgart LJ, et al: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14:3408-3415, 2008
11. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988
12. Worthley DL, Leggett BA: Colorectal cancer: Molecular features and clinical opportunities. Clin Biochem Rev 31:31-38, 2010
13. Leggett B, Whitehall V: Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 138:2088-2100, 2010
14. Shen L, Toyota M, Kondo Y, et al: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 104:18654-18659, 2007 (Pubitemid 350210752)
15. Yang S, Farraye FA, Mack C, et al: BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: Relationship to histology and CpG island methylation status. Am J Surg Pathol 28:1452-1459, 2004 (Pubitemid 39425511)
16. Rosenberg DW, Yang S, Pleau DC, et al: Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res 67:3551-3554, 2007 (Pubitemid 46762136)
17. Huang CS, Farraye FA, Yang S, et al: The clinical significance of serrated polyps. Am J Gastroenterol 106:229-240, 2011
18. Hutchins G, Southward K, Handley K, et al: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261-1270, 2011
19. Samowitz WS, Sweeney C, Herrick J, et al: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65:6063-6069, 2005
20. Kim IJ, Kang HC, Jang SG, et al: Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations. Carcinogenesis 27:392-404, 2006 (Pubitemid 43372868)
21. Popovici V, Budinska E, Tejpar S, et al: Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 30:1288- 1295, 2012
22. Van Cutsem E, Labianca R, Bodoky G, et al: Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117-3125, 2009
23. Kennedy RD, Bylesjo M, Kerr P, et al: Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol 29:4620-4626, 2011
24. Gray RG, Quirke P, Handley K, et al: Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 29:4611-4619, 2011
25. Salazar R, Roepman P, Capella G, et al: Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29:17-24, 2011
26. Souglakos J, Philips J, Wang R, et al: Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 101:465-472, 2009
27. Zujewski JA, Kamin L: Trial assessing individualized options for treatment for breast cancer: The TAILORx trial. Future Oncol 4:603-610, 2008
28. Kefford R, Arkenau H, Brown MP, et al: Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28:611s, 2010 (suppl 15; abstr 8503)
29. Kannengiesser C, Spatz A, Michiels S, et al: Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol 1:425-430, 2008